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Abstract
Background: A previous economic analysis of self-management, that is, self-monitoring with self-titration of antihy-
pertensive medication evaluated cost-effectiveness among patients with uncomplicated hypertension. This study con-
sidered cost-effectiveness of self-management in those with raised blood pressure plus diabetes, chronic kidney disease
and/or previous cardiovascular disease.
Design and methods: A Markov model-based economic evaluation was undertaken to estimate the long-term cost-
effectiveness of self-management of blood pressure in a cohort of 70-year-old ‘high risk’ patients, compared with usual
care. The model used the results of the TASMIN-SR trial. A cost–utility analysis was undertaken from a UK health and
social care perspective, taking into account lifetime costs of treatment, cardiovascular events and quality adjusted life
years. A subgroup analysis ran the model separately for men and women. Deterministic sensitivity analyses examined the
effect of different time horizons and reduced effectiveness of self-management.
Results: Base-case results indicated that self-management was cost-effective compared with usual care, resulting in
more quality adjusted life years (0.21) and cost savings (–£830) per patient. There was a 99% chance of the intervention
being cost-effective at a willingness to pay threshold of £20,000 per quality adjusted life year gained. Similar results were
found for separate cohorts of men and women. The results were robust to sensitivity analyses, provided that the blood
pressure lowering effect of self-management was maintained for more than a year.
Conclusion: Self-management of blood pressure in high-risk people with poorly controlled hypertension not only
reduces blood pressure, compared with usual care, but also represents a cost-effective use of healthcare resources.
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Background
Hypertension is a leading risk factor for cardiovascular
mortality and morbidity worldwide.1,2 Despite evidence
of cost saving from antihypertensive treatment,3 and
improvements in blood pressure (BP) monitoring, man-
agement and treatment,3,4 significant numbers of people
remain inadequately controlled hence new models of care
are required.5 Self-management of hypertension, in which
an individual self-monitors their own BP and adjusts their
own medication has been shown to lead to significantly
lower BP in hypertension, including in those with higher
cardiovascular risk.6,7
The only economic analysis of self-management in the
control of hypertension to date demonstrated that
tele-monitoring with self-titration in uncomplicated
hypertension was highly cost-effective, with incremental
cost-effectiveness ratios below £5000 per quality adjusted
life year (QALY) gained for men and women, when mod-
elled over patient lifetime.8 However, subgroup analysis in
the main trial suggested that the intervention might not be
as effective in those with significant comorbidities,
although patient numbers for this subgroup were small.7
Therefore, the TASMIN-SR trial was undertaken to
determine the effect of self-monitoring with self-titration
of antihypertensive medication on systolic BP among
hypertensive patients with suboptimal control and pre-
existing cardiovascular disease, diabetes mellitus (DM)
and/or chronic kidney disease (CKD), compared with
usual care. A model-based probabilistic cost–utility ana-
lysis was undertaken as part of this study to assess the
long-term cost-effectiveness of the self-management inter-
vention in a ‘high risk’ patient population, compared with
usual care.
Methods
A Markov cohort model, built in TreeAge Pro
(TreeAge Software Inc, Williamstown, MA, USA),
was developed to estimate the long-term cost-
effectiveness of self-management of BP compared with
usual care, in patients with hypertension and a history
of stroke, coronary heart disease (CHD), DM or CKD.
The analysis used the results of the TASMIN-SR trial
on BP, extrapolating these to long-term risk of cardio-
vascular endpoints (see below). Full details of the trial
methods and results have been described in detail else-
where.6,9 The model was run over a lifetime (30 year)
time horizon using a six-month time cycle, with results
presented from a UK National Health Service (NHS)
and personal social services perspective.
Study population
The base case analysis considered a cohort of 70-year-old
patients (39% women) with suboptimal hypertension,
BP 130/80 mmHg at baseline, combined with a his-
tory of stroke, CHD, DM or CKD.6 Patients had at
least one of four main underlying conditions (DM,
stroke, CHD and CKD), to be eligible with 15 possible
combinations of high risk conditions in total. Further
details of the combined risk conditions are available in
supplementary Table 2.
Interventions
Patients randomly assigned to usual care booked an
appointment for a routine BP pressure check and medi-
cation review with the study general practitioner.
Thereafter, usual care consisted of the participants
seeing their general practitioner and or nurse for rou-
tine BP measurement and adjustment of medication at
the discretion of the health professional. Patients ran-
domly assigned to self-management were trained to
self-monitor BP and to self-titrate their antihyperten-
sive medication following a predetermined plan, in two
or three sessions, each lasting around an hour.
Following training, patients adjusted their antihyper-
tensive medication based on their monthly self-
monitored BP readings.9
Model structure
A patient entered the model in the high-risk health state
and could move to another health state if they experi-
enced one of three possible cardiovascular events
(stroke, myocardial infarction (MI), unstable angina
(UA)), or died from other causes (Figure 1). After a car-
diovascular event, individuals could survive from that
event or die within the first six months. Those who sur-
vived an event subsequently moved to a chronic health
state for that condition until death, with no recurrences of
cardiovascular events. For each chronic health state, an
ongoing healthcare cost was applied every time cycle and
quality of life was permanently reduced. Movement
between health states was defined by transition probabil-
ities, which represented the risk of experiencing an event
within each six-month time cycle.
Model parameters
Patient level data from the TASMIN-SR trial were
used to reflect the cardiovascular disease history of
patients entering the Markov model. The probabilities
of experiencing a stroke, MI or developing UA were
obtained from published literature for hypertensive
patients with each of the high-risk conditions10–14
(Table 1).15–17 When the model required probabilities
that were not available in the literature (for a given age
group, gender or combination of high risk conditions),
missing values were estimated through extrapolation
Penaloza-Ramos et al. 903
(see supplementary document). For patients presenting
with two or more high risk conditions, the probability
of an event was calculated as the sum of the two individ-
ual risk probabilities (supplementary Tables 1 and 2).
Systolic BP reductions recorded in the trial at six
months (11.4 mmHg and 5.5 mmHg for the interven-
tion and control arms) and at 12 months (15.0 mmHg
and 5.8 mmHg for the intervention and control arms)
were extrapolated to age-related risk reductions for
CHD (comprising both MI and UA) and stroke,
using Law et al.18 (Table 1). Relative risks for CHD
and stroke related to six and 12 month BP reductions
are reported in Table 1. The model assumed that BP
remained static for the first six-month cycle of the
model, then reduced as per the six-month trial results
for the second model cycle followed by the 12-month
trial reductions thereafter with the between groups dif-
ferences assumed constant in the base case. The prob-
abilities of death from MI and stroke within a year of
the event are reported in Table 1 and applied to the first
year after an event (first two cycles in the model). Life
tables were used to determine overall mortality,
dependent on age and gender.19
Resource use and costs
Costs are reported in UK pounds at 2011/2012 prices.
Resource use related to ongoing BP monitoring in pri-
mary care, self-management and prescription of
antihypertensive agents was obtained from
the TASMIN-SR trial at 12 months follow-up.
For self-management, equipment and training costs
were annuitised at an annual rate of 3.5% and based
on a lifetime of five years.20 Replacement costs for the
equipment and training were included at five yearly
intervals over the lifetime of the model (see supplemen-
tary Table 3). Equipment used by individuals who died
within any five-year interval was assumed to be dis-
carded. Unit costs were applied to resource use and
mean patient costs per six months were calculated for
both randomly assigned groups, and applied to the ini-
tial high risk health state. Costs for acute and chronic
cardiovascular event states were obtained from pub-
lished studies14,21–23 (see Table 1).
Utility values
The primary outcome measure was QALYs. All utility
scores used in the model are shown in Table 1. The
utility values for the starting high risk health state
were obtained from the TASMIN-SR trial, in which
the overall mean EQ-5D score for hypertensive patients
at baseline was used to estimate utilities. This was
adjusted for age group using weights calculated from
Ara and Brazier,24 which allowed the overall reduction
in quality of life with increasing age to be incorporated
in the model. Acute events were assumed to happen
approximately three months into a six-month cycle
and individuals stayed in that acute state for three
months before moving into a chronic state. Therefore,
utilities for the acute state were applied mid-way
through the six-month cycle and chronic health state
Event free
Stroke
Survive
Die
Survive
Die
Myocardial infarction (MI)
Unstable angina (UA)
Dead
Survive
Survive
Survive
Die
Die
Die
Dead
Post MI
Post stroke
Self-management
Usual care
···
High risk condition *
Post unstable angina
Figure 1. Markov model.
*In the Markov model patients can enter through any of fifteen combinations of high risk conditions.
Note: The Markov model is displayed for the self-management strategy only however, the model is identical for the usual care strategy.
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Table 1. Model parameters.
Parameter Value Source
Reduction in systolic BP at 12 months (mmHg) TASMIN-SR trial6
Self-management 15.0
Usual care 5.8
Reduction in systolic
BP at 6 months (mmHg)
TASMIN-SR trial6
Self-management 11.4
Usual care 5.5
Annual transition probabilities
CVD events for patients with DM NICE Diabetes guidelines,
Appendix D112
Stroke
60–69 years old 0.0196
70–79 years old 0.0262
80–89 years old 0.0298
MI
60–69 years old 0.0089
70–79 years old 0.0100
80–89 years old 0.0111
UA
60–69 years old 0.0041
70–79 years old 0.0047
80–89 years old 0.0052
CVD events for
patients with CKD
Kerr et al.11
Stroke
60–69 years old 0.0072
70–79 years old 0.0147
80–89 years old 0.0189
MI
60–69 years old 0.0051
70–79 years old 0.0113
80–89 years old 0.0171
UA
60–69 years old 0.0024
70–79 years old 0.0054
80–89 years old 0.0081
CVD events for patients
with a previous stroke
PROGRESS & NICE,
lipid modification guidelines10,14
Stroke
60–69 years old 0.0348
70–79 years old 0.0589
80–89 years old 0.0713
MI
60–69 years old 0.0139
70–79 years old 0.0232
80–89 years old 0.0232
UA
60–69 years old 0.0139
70–79 years old 0.0232
80–89 years old 0.0232
CVD events for
patients with CHD
NICE, lipid modification guidelines14
and NICE hypertension guidelines4
(continued)
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Table 1. Continued
Parameter Value Source
Stroke
60–69 years old 0.0359
70–79 years old 0.0588
80–89 years old 0.0713
MI
60–69 years old 0.0666
70–79 years old 0.1112
80–89 years old 0.1112
UA
60–69 years old 0.0528
70–79 years old 0.0881
80–89 years old 0.0881
Age-related relative
risks at 12 months
(95% CI)
TASMIN-SR trial
& Law et al.6,18
MI and UA – self-management
60–69 years old 0.63 (0.60, 0.66)
70–79 years old 0.68 (0.64, 0.71)
80–89 years old 0.74 (0.70, 0.78)
Stroke – self-management
60–69 years old 0.53 (0.49, 0.57)
70–79 years old 0.59 (0.55, 0.64)
80–89 years old 0.74 (0.69, 0.79)
MI and UA – usual care
60–69 years old 0.83 (0.81, 0.84)
70–79 years old 0.85 (0.84, 0.87)
80–89 years old 0.89 (0.87, 0.90)
Stroke – usual care
60–69 years old 0.77 (0.75, 0.79)
70–79 years old 0.81 (0.79, 0.83)
80–89 years old 0.89 (0.86, 0.91)
Age-related relative
risks at 6 months
(95% CI)
TASMIN-SR trial
& Law et al.6,18
MI and UA –
self-management
60–69 years old 0.71 (0.68, 0.73)
70–79 years old 0.75 (0.72, 0.77)
80–89 years old 0.80 (0.76, 0.83)
Stroke – self-management
60–69 years old 0.62 (0.59, 0.66)
70–79 years old 0.68 (0.64, 0.71)
80–89 years old 0.80 (0.76, 0.84)
MI and UA – usual care
60–69 years old 0.83 (0.82, 0.85)
70–79 years old 0.86 (0.85, 0.87)
80–89 years old 0.89 (0.87, 0.91)
Stroke – usual care
60–69 years old 0.77 (0.75, 0.80)
70–79 years old 0.81 (0.80, 0.84)
80–89 years old 0.89 (0.87, 0.91)
Probability of death for those who have experienced an event
Fatal stroke 0.23 Bamford et al.15
(continued)
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utilities were applied at the start of the subsequent cycle
(Table 1). Health state utilities for cardiovascular
events were applied multiplicatively to the age-related
high risk health state utility values.
Analysis
A cost–utility analysis was undertaken from a UK NHS
and personal social services perspective. For the base-
case analysis, 15 separate cost-effectiveness analyses
were run, one for each combination of high risk condi-
tions assessed in the model. The final cost-effectiveness
results correspond to the trial population-weighted aver-
age of costs and QALYs and are reported in terms of the
incremental cost per QALY gained.25 Analyses were also
separately run for men and women. Costs and outcomes
were discounted at an annual rate of 3.5%.26
Uncertainty in the model results was assessed using
sensitivity analyses. Deterministic sensitivity analysis
was undertaken around key parameters and assump-
tions. The time horizon for the model was varied
from 30 years (lifetime) to between one year and 20
years, to determine whether the intervention was cost-
effective in the shorter term. The assumption regarding
the long-term effectiveness of the intervention was
tested by assessing the impact of limiting the additional
effect on BP lowering to years of self-management.1,2,5,10
Additional sensitivity analyses altered long-term
Table 1. Continued
Parameter Value Source
Fatal MI ONS, deaths registry 2011
& Kerr et al.11,19
65–74 years old 0.23
75–84 years old 0.39
85 and over 0.52
Costs (UK £)
Cost for the initial statea TASMIN-SR trial, Curtis
& BNF6,16,17
Self-managementb 183
Usual care 125
Costs of acute disease one-off cost
Stroke 11,020 Youman et al.23
MI 5487 Robinson et al.22
UA 3292 Assumed 60% of MI
Costs for long-term (chronic) disease per year
Stroke 2721 Youman et al23
MI 572 NICE, lipid modification guidelines 14
UA 572 NICE, lipid modification guidelines14
Utilities
Utilities for initial health state
Self-management and usual care TASMIN-SR trial6
65–74 years old 0.81
75–84 years old 0.74
85 and over 0.71
Utilities for acute events NICE, lipid modification guidelines14
UA 0.77
MI 0.76
Stroke 0.63
Utilities for long-term (chronic) disease NICE, lipid modification guidelines14
UA 0.88
MI 0.88
Stroke 0.63
Dead 0.00 By definition
aIncluded annual costs of drugs per patient, average general practitioner and practice nurse cost of consultation(s) and the costs
of the intervention. The cost difference between self-monitoring and usual care was driven by the cost of the intervention bFor
greater detail see supplementary document. CVD: cardiovascular disease; CKD: chronic kidney disease; DM: diabetes mellitus;
MI: myocardial infarction; UA: unstable angina.
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cardiovascular event costs by 30% (up and down).
Finally, all analyses were re-run using the unadjusted
trial data, which showed marginally smaller reductions
in BP (11.4 mmHg and 5.8 mmHg for the intervention
and control arms at six months and 14.9 mmHg and 6.0
mmHg, respectively, at 12 months). When possible, data
were entered into the model as distributions in order that
a probabilistic sensitivity analysis could be undertaken to
incorporate parameter uncertainty. Gamma distributions
were fitted to all costs obtained from the TASMIN-SR
trial and beta distributions were applied to the utility
values. The parameters used for these distributions are
shown in Table 1. The probabilistic sensitivity analysis
was run with 10,000 second-order Monte Carlo simula-
tions and cost-effectiveness planes and cost-effectiveness
acceptability curves constructed to estimate the probabil-
ity of self-management being cost-effective at different
willingness-to-pay thresholds.20
Results
In the base-case analysis, self-management of BP was dom-
inant compared to usual care, being cheaper and more
effective (Table 2). Self-management was associated with
mean cost savings of £830 per patient for the total popu-
lation (self-management £7357 vs. usual care £8187) and a
gain of 0.21 QALYs (6.25 vs. 6.03, respectively). This
dominance was demonstrated for both men and women
(Table 2). In the cost-effectiveness plane (Figure 2), all
results are in the north-east and south-east quadrants indi-
cating that self-management is always more effective but
with greater uncertainty around the difference in costs. The
cost-effectiveness acceptability curve shows that the prob-
ability of self-management of BP being cost-effective com-
pared with usual care was at least 99% if decision-makers
were willing to pay £20,000 per QALY gained. At a lower
threshold of £10,000 per QALY, the probability of the
intervention being cost-effective compared with usual
care was still high at 97% (Figure 2).
A sensitivity analysis of time horizon demonstrated
that self-management is dominant if the horizon is
two years or more (Table 3). Similarly, if the impact
of self-management on BP is time limited, the cost-
effectiveness is reduced – but the intervention is still
cost-effective provided that the effect is sustained
for one year (first two cycles) (Table 4). Other sensitivity
analyses (costs and reduced impact on BP) did not change
the overall results (see supplementary Tables 4–6).
Discussion
This is the first study to present results of the cost-
effectiveness of self-management of BP compared with
usual care in a high risk population with suboptimally
managed hypertension and significant cardiovascular
comorbidity. The base-case analysis suggests that self-
management of BP is cost-effective and is likely to be
dominant (i.e. it is less costly and produces more
QALYs) compared to usual care.
The main driver of this result is the estimated decline
in the risk of cardiovascular events associated with the
observed additional BP lowering achieved with self-
management, and this explanation also holds for the
greater benefit seen for men. This result was robust to
sensitivity analysis unless the time horizon was reduced
below two years or the observed BP lowering effect of
self-management did not continue beyond a year.
Relationship with other literature
Previous economic studies have evaluated the cost-
effectiveness of self-monitoring rather than self-
management (self-monitoring plus self-titration of
antihypertensive medication) and only one previous eco-
nomic analysis of self-management has been undertaken
(TASMINH2),8 which found self-management to be
cost-effective (£1624 and £4923 per QALY gained for
men and women, respectively).8 In this analysis, we
Table 2. Results of cost-effectiveness analysis.
Costs QALYs Incremental cost Incremental QALYs ICER
Total population
Usual care 8187 6.0326
Self-management 7357 6.2466 –830 0.2139 Dominant
Women
Usual care 7338 6.2467
Self-management 6579 6.4456 –759 0.1988 Dominant
Men
Usual care 8654 5.9035
Self-management 7791 6.1257 –864 0.2221 Dominant
QALYs: quality adjusted life years; ICER: Incremental Cost-Effectiveness Ratio.
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found self-management to be even more cost-effective,
reflecting the higher number of cardiovascular events
predicted to have been prevented in the higher risk popu-
lation, and the slightly greater reductions in BP that were
observed in the TASMIN-SR trial.
Strengths and limitations
This study used cost and outcome data of trial partici-
pants,6 who may differ from similar patients not taking
part in the trial for instance being more adherent and
healthier.27 The strongly positive results, however, sug-
gest that such an intervention would be cost-effective
even in a less compliant population. The costs of long-
term and acute care were taken from estimates in the
literature and a number of assumptions were made
about the annual probabilities of cardiovascular
events by risk conditions based on best published
information. A key assumption was that of the pro-
longed effectiveness of the intervention. In both
TASMINH2 and TASMIN-SR, the difference in BP
reduction between trial arms continued to diverge
between six and 12 months, suggesting that the effect
may be maintained over time. Indeed, an 18 month
post-trial follow-up of the HSM self-management trial
found that BP continued to diverge over time, suggest-
ing our assumption of maintenance of effect may even
be conservative.28 The sensitivity analyses showed that
even if BP differences lasted only one further year and
then returned to the effectiveness of usual care, self-
management is still likely to be cost-effective. For sim-
plicity, the model did not include subsequent cardiovas-
cular events. Given that the main driver of costs was
events and the main driver of events was BP, it would
be expected that a model including secondary and sub-
sequent events would show self-management to be even
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more cost-effective than usual care. The model con-
siders patients with comorbidities and additional risk
factors (e.g. age, gender). Arguably, a more complex
model such as individual patient level simulation
could be more appropriate in this situation, as this
type of model can incorporate patient history more effi-
ciently, overcoming the limitations of Markov
models.29 Finally, an assumption has been made
regarding the differential effect of BP lowering between
the intervention and control groups. Systematic reviews
suggest that lowering BP below 140/90 mmHg is as
effective as lowering BP to 140/90 mm Hg,18 but it is
fair to say that the evidence of benefit is stronger in
stroke and DM than in CHD or CKD.10,30–32
Table 3. Sensitivity analyses: cost-effectiveness by time horizon.
Costs QALYs
Incremental
cost
Incremental
QALYs ICER
20 years
Usual care 7709 5.8830
Self-management 6919 6.0975 –789 0.2145 Dominant
10 years
Usual care 5242 4.7756
Self-management 4675 4.9252 –567 0.1496 Dominant
5 years
Usual care 2882 3.1178
Self-management 2554 3.1742 –328 0.0564 Dominant
3 years
Usual care 1690 2.0859
Self-management 1535 2.1044 –155 0.0186 Dominant
2 years
Usual care 1116 1.4651
Self-management 1056 1.4718 –59 0.0067 Dominant
1 year
Usual care 603 0.7729
Self-management 625 0.7736 22 0.0006 34,791
QALYs: quality adjusted life years; ICER: Incremental Cost-Effectiveness Ratio.
Table 4. Sensitivity analyses: cost-effectiveness by reducing the additional effect of self-management to blood
pressure lowering at four different time points.
Time horizon Costs QALYs
Incremental
cost
Incremental
QALYs ICER
10 years
Usual care 8187 6.0326
Self-management 7530 6.2242 –657 0.1916 Dominant
5 years
Usual care 8187 6.0326
Self-management 7876 6.1623 –311 0.1297 Dominant
2 years
Usual care 8187 6.0326
Self-management 8259 6.0757 71 0.0430 1660
1 year
Usual care 8187 6.0326
Self-management 8382 6.0454 195 0.0127 15,341
QALYs: quality adjusted life years; ICER: Incremental Cost-Effectiveness Ratio.
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Clinical implications
These results suggest that the benefits of BP reduction
seen in the trial can be achieved in a highly cost-effec-
tive manner. The up-front costs of implementation of
self-management of hypertension in high risk groups
are relatively modest (£14.6 equipment and £20.0 train-
ing), and are soon repaid by future maintenance of
quality of life and reductions in costs from reduced
cardiovascular events. The very high likelihood of
cost-effectiveness from both this and the previous ana-
lyses suggest that self-management is a strong candi-
date for implementation.
Conclusions
The results of this model-based economic evaluation
suggest that self-management of hypertension in high
risk patients is a cost-effective strategy in the short and
long term, resulting in QALY gains and cost savings.
Self-management of BP in high risk patients represents
an important new addition to the management of
hypertension in primary care.
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